What is PAVmed Inc.'s market cap?

PAVmed Inc. (PAVM) has a market capitalization of $39.7M and trades on NASDAQ.

Who are PAVmed Inc.'s competitors?

PAVmed Inc.'s key competitors include Guardant Health, Lucid Diagnostics Inc. Common Stock, Onconetix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does PAVmed Inc. partner with?

PAVmed Inc.'s notable partners include UpScript, LLC, Highmark Blue Cross Blue Shield, The Ohio State University Comprehensive Cancer Center, and others.

What subsidiaries does PAVmed Inc. have?

PAVmed Inc.'s subsidiaries include Lucid Diagnostics Inc., Veris Health Inc..

Where is PAVmed Inc. headquartered?

PAVmed Inc. is headquartered in United States of America and employs approximately 107 people. It has been publicly traded since 2016.

PAVmed Inc.

PAVM

PAVmed Inc. is a diversified commercial-stage life sciences company that develops and commercializes innovative healthcare technologies across medical devices, diagnostics, and digital health.

Market cap

$39.73M+283%

Table of contents

Earnings

Q1 2026 report

May 15, 2026

Revenue$22.0KMiss by $52.0K EPS-$1.17Miss by $0.48

Read the full report

Next report

Aug 13, 2026 (in a month)

Revenue estimate$48.0K

EPS estimate-$0.63

Competitors

By market cap

Guardant Health$21.8B+254%

GRAIL, Inc.$3.3B+102%

Personalis, Inc.$1.5B+160%

Lucid Diagnostics$188.9M+67.9%

PAVmed Inc.$39.7M+289%

ADV

Advanced Biomed Inc. Common Stock$8.8M-38.8%

Cardio Diagnostics Holdings Inc.$5.5M-16.9%

ONC

Onconetix, Inc.$3.6M+61.7%

By revenue growth

Guardant Health+39.6%

Lucid Diagnostics+23.0%

GRAIL, Inc.+19.4%

Personalis, Inc.-24.7%

By net margin

Guardant Health-40.1%+13.7pp

Personalis, Inc.-148.11%-50.0pp

GRAIL, Inc.-253.22%+1,211pp

Lucid Diagnostics-876.72%+605pp

Profile

PAVmed Inc. is a diversified commercial-stage life sciences company that develops and commercializes innovative healthcare technologies across medical devices, diagnostics, and digital health. The company operates through a shared services model, managing multiple independently financed subsidiaries to advance products from early-stage development to commercialization. Its core value proposition focuses on addressing unmet clinical needs in cancer prevention and personalized patient monitoring.

Competitive position

A commercial-stage innovator in esophageal cancer diagnostics with the first and only commercially available non-invasive screening tool for Barrett's Esophagus.

GeographiesUnited States, European Union

Customer segmentsHealthcare Providers, Government Agencies, Enterprise, Patients

Business modelDirect-to-consumer, Subscription SaaS, B2B, Licensing

SuppliersThird-party contract manufacturers, Academic research institutions (Case Western Reserve University, Duke University), Specialized component suppliers

CustomersPhysician offices, Hospital systems, U.S. Department of Veterans Affairs, Self-insured employers

CountryUnited States of America

Listed2016

Employees107.0

CEOLishan Aklog

SectorHealthcare

IndustryMedical - Devices

Websitepavmed.com

FilingsSEC EDGAR

Questions, answered.

What is PAVmed Inc.'s market cap?: PAVmed Inc. (PAVM) has a market capitalization of $39.7M and trades on NASDAQ.
Who are PAVmed Inc.'s competitors?: PAVmed Inc.'s key competitors include Guardant Health, Lucid Diagnostics Inc. Common Stock, Onconetix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does PAVmed Inc. partner with?: PAVmed Inc.'s notable partners include UpScript, LLC, Highmark Blue Cross Blue Shield, The Ohio State University Comprehensive Cancer Center, and others.
What subsidiaries does PAVmed Inc. have?: PAVmed Inc.'s subsidiaries include Lucid Diagnostics Inc., Veris Health Inc..
Where is PAVmed Inc. headquartered?: PAVmed Inc. is headquartered in United States of America and employs approximately 107 people. It has been publicly traded since 2016.